A Danish nationwide questionnaire study of hepatitis B virus screening before immunosuppressive therapy.
|Abstract||Difficulty in identifying patients who are at risk for hepatitis B virus (HBV) reactivation makes it import-ant to screen for HBV before initiating immunosuppressive therapy. The aim of this study was to investigate screening procedures for HBV infection before initiation of immunosuppressive therapy and to explore HBV treatment strategies.|
Management of the risk of hepatitis B virus reactivation in patients receiving immunosuppressive and immunomodulatory agents in internal medicine: data from the REACTI-B survey and proposal for a management algorithm.
|Journal Title||danish medical journal|
|Publication Year Start||2017-01-01|
PMID- 28260595 OWN - NLM STAT- MEDLINE DA - 20170306 DCOM- 20170313 LR - 20170313 IS - 2245-1919 (Electronic) IS - 2245-1919 (Linking) VI - 64 IP - 3 DP - 2017 Mar TI - A Danish nationwide questionnaire study of hepatitis B virus screening before immunosuppressive therapy. LID - A5341 [pii] AB - INTRODUCTION: Difficulty in identifying patients who are at risk for hepatitis B virus (HBV) reactivation makes it import-ant to screen for HBV before initiating immunosuppressive therapy. The aim of this study was to investigate screening procedures for HBV infection before initiation of immunosuppressive therapy and to explore HBV treatment strategies. METHODS: All Danish units of haematology, oncology, dermatology, rheumatology and gastroenterology using immunosuppressive agents were invited to fill out a questionnaire for The Danish Database for Hepatitis B and C. RESULTS: A total of 28 (53%) of the 53 included units answered the questionnaire, of which 25 (89.3%) had a guideline regarding screening for HBV serological markers prior to immunosuppressive therapy, but only ten (37%) had a guideline that is in line with the joint guidelines from the national Danish Societies of Infectious Diseases and Gastroenterology and Hepatology. Nineteen (76%) units had a strategy regarding treatment for reactivation before initiating immunosuppressive therapy in case of positive HBV serology. It was not possible to determine the number of HBV reactivations as this was not registered in the ICD-10 system. The Danish Medicines Agency had one report of reactivation. CONCLUSIONS: A minority of the units had screening guidelines for HBV reactivation that were in line with the guidelines of the national scientific societies. Screening in accordance with these recommendations should be a goal for all Danish units in order to prevent HBV reactivation. FUNDING: none. TRIAL REGISTRATION: not relevant. FAU - Bunyoz, Kristine Ifigenia AU - Bunyoz KI AD - [email protected] FAU - Krarup, Henrik AU - Krarup H FAU - Weis, Nina AU - Weis N LA - eng PT - Journal Article PL - Denmark TA - Dan Med J JT - Danish medical journal JID - 101576205 RN - 0 (Immunosuppressive Agents) SB - IM MH - Cross-Sectional Studies MH - Denmark MH - Hepatitis B/blood/*diagnosis/prevention & control MH - Hepatitis B virus/isolation & purification/physiology MH - Humans MH - Immunosuppressive Agents/*adverse effects MH - Mass Screening MH - Practice Guidelines as Topic MH - Risk Factors MH - *Secondary Prevention MH - Surveys and Questionnaires MH - Virus Activation EDAT- 2017/03/07 06:00 MHDA- 2017/03/14 06:00 CRDT- 2017/03/07 06:00 AID - A5341 [pii] PST - ppublish SO - Dan Med J. 2017 Mar;64(3). pii: A5341.
<?xml version="1.0" encoding="UTF-8"?> <b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" > </b:Sources>